Continuing Education Activity

Isotretinoin is an oral retinoid used to treat severe, recalcitrant nodular acne that does not respond to conventional therapies such as systemic antibiotics. The medication primarily acts by reducing sebaceous gland size and sebum production, normalizing keratinization, and exerting anti-inflammatory effects in the skin. This course examines the United States Food and Drug Administration–approved and off-label indications of isotretinoin, its pharmacological properties, and the mechanisms of action that underlie its clinical efficacy. Detailed attention is given to dosing strategies, pharmacokinetics, and monitoring requirements to ensure the safe and effective use of the medication. Common and severe adverse reactions, contraindications, and potential drug-drug interactions are also reviewed, with special focus on toxicology, pregnancy prevention programs, and laboratory monitoring to mitigate treatment-associated risks.

The course enables participants to develop a comprehensive understanding of isotretinoin therapy within a structured, evidence-based framework. Emphasis is placed on collaborative care among dermatologists, pharmacists, nurses, and primary care clinicians, as shared communication and coordinated monitoring significantly reduce the risk of preventable harm. Interprofessional teamwork ensures timely identification of adverse effects, adherence to pregnancy prevention protocols, and reinforcement of patient education, leading to improved safety and long-term therapeutic success. Through this integrated approach, healthcare professionals strengthen both clinical outcomes and patient trust in acne management.

Objectives:

• Evaluate the therapeutic mechanism of action of isotretinoin.
• Differentiate between the United States Food and Drug Administration–approved indications and off-label uses of isotretinoin.
• Assess the adverse reactions associated with isotretinoin therapy.
• Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from isotretinoin therapy.

Indications

United States Food and Drug Administration–Approved Indications

Isotretinoin is an oral medication that affects sebaceous glands and is used to treat severe acne. The United States Food and Drug Administration (FDA) approved the drug in 1982 for the treatment of severe nodular acne that is resistant or unresponsive to conventional therapy, including systemic antibiotics. According to the American Academy of Dermatology guidelines, isotretinoin is recommended for patients with severe acne or those who have not responded to standard treatments, including oral and topical therapies. Patients with acne who experience significant psychosocial burden or scarring should also be considered candidates for isotretinoin. For patients with severe acne, the guidelines conditionally recommend traditional daily dosing of isotretinoin over intermittent dosing. Either standard isotretinoin or lidose-isotretinoin can be considered.[1] Lidose-isotretinoin has greater bioavailability than traditional isotretinoin due to its presolubilized lipid matrix.[2]

Off-Label Uses

Isotretinoin has been used to treat moderate acne, cutaneous T-cell lymphomas, and to prevent squamous cell carcinoma in high-risk patients.[3] Isotretinoin is part of the treatment regimen for high-risk patients with neuroblastoma.[4][5] Clinicians have also used isotretinoin for the treatment of rosacea, folliculitis, and pyoderma faciale (also known as rosacea fulminans).[6][7][8][9] A systematic review and meta-analysis indicated that low-dose isotretinoin (≤0.5 mg/kg/d) significantly reduces lesion count and erythema in patients with rosacea, with improvements sustained after treatment cessation. This formulation outperformed topical treatments in terms of efficacy, with good safety and tolerability, and minimal serious adverse events.[10]

Mechanism of Action

Isotretinoin is an orally administered systemic retinoid. This medication is an effective acne therapy at a daily dose of 0.5 to 1.0 mg/kg. Although the exact mechanism of action is unknown, isotretinoin inhibits sebaceous gland function and keratinization at pharmacologic doses. The drug has been observed to reduce sebaceous gland size and sebum production. In patients with neuroblastoma (off-label use), isotretinoin has been shown to reduce cell proliferation and induce differentiation.[6][11]

Pharmacokinetics

Absorption: Isotretinoin achieves its highest plasma concentration around 6.4 hours after food intake, whereas the peak occurs about 2.9 hours after an empty stomach. Food may enhance the absorption of isotretinoin. However, this variation is not considered clinically crucial, so that isotretinoin can be taken with or without meals. Advances in isotretinoin formulations, including lidose encapsulation and micronization, have reduced bioavailability variability between fed and fasted states, ensuring more consistent dosing.[12]

Distribution: Isotretinoin is highly protein-bound in plasma, with over 99.9% bound to albumin.

Metabolism: Isotretinoin is primarily metabolized in the liver by the cytochrome P450 enzymes CYP2C8, CYP2C9, CYP3A4, and CYP2B6.[13] Following oral administration, isotretinoin undergoes conversion into several metabolites, including 4-oxo-isotretinoin, retinoic acid (tretinoin), and 4-oxo-retinoic acid (4-oxo-tretinoin), which are all detectable in human plasma.[14][15] These metabolites retain retinoid activity in vitro, though their clinical significance remains unclear.

Elimination: The elimination half-lives of isotretinoin and its major metabolite, 4-oxo-isotretinoin, are 18 hours and 38 hours, respectively. Isotretinoin and its metabolites are predominantly excreted through feces and urine.

Administration

Available Dosage Forms and Strengths

Isotretinoin is administered orally as a capsule. The drug has low bioavailability and is highly lipophilic. The patient can maximize oral absorption of isotretinoin by taking it with a meal. Isotretinoin should be taken with a full glass of water to avoid esophageal irritation. Isotretinoin is available as oral capsules in strengths of 10, 20, 25, 30, 35, and 40 mg. Additionally, it is offered as a micronized capsule formulation in strengths of 8, 16, 20, 24, 28, and 32 mg.

Adult Dosage

The initial dose of isotretinoin is typically 0.5 mg/kg/d, which is gradually increased to 1.0 mg/kg/d based on patient tolerance. Typical therapy requires 15 to 20 weeks of daily isotretinoin administration to achieve complete and prolonged disease remission.[6][16] For adults with severe acne, including scarring and trunk involvement, an increased isotretinoin dosage of 2 mg/kg/d may be prescribed, administered in divided doses.

Specific Patient Populations

Hepatic impairment: Liver function abnormalities occur in up to 15% of patients taking isotretinoin, although significant elevations necessitating discontinuation are uncommon. The mechanism of injury is not fully understood, but it may involve a direct toxic effect, with higher doses associated with a higher frequency. These abnormalities are generally asymptomatic and transient, often resolving without discontinuation. Regular monitoring of liver tests is advised, and isotretinoin should be discontinued if aminotransferase levels exceed 5 times the upper limit of normal or if symptoms such as jaundice develop.[17]

Renal impairment: No dosage adjustments are provided in the product labeling; therefore, it should be used with caution in patients with renal impairment.

Pregnancy considerations: Isotretinoin is contraindicated in pregnancy due to its potential to cause severe fetal harm, including major congenital malformations, spontaneous abortions, and premature births. Even brief exposure during pregnancy can result in life-threatening congenital disabilities, and there is no reliable method to determine prenatally if a fetus has been affected. Documented malformations include defects in the face, eyes, ears, skull, central nervous system, cardiovascular system, thymus, and parathyroid glands. Cognitive impairments, which may be suggested by IQ scores below 85, have also been reported in children exposed in utero. If a patient becomes pregnant while undergoing isotretinoin therapy, the medication must be stopped immediately, and the patient should be referred to an obstetrician or gynecologist for further evaluation and counseling. Any suspected fetal exposure must be reported to the FDA through MedWatch (1-800-FDA-1088) and the iPLEDGE pregnancy registry (1-866-495-0654 or www.ipledgeprogram.com). Isotretinoin is available exclusively through a restricted REMS (Risk Evaluation and Mitigation Strategy) program, which includes a pregnancy exposure registry to monitor pregnancy outcomes in patients exposed to isotretinoin. According to the study, isotretinoin exposure during pregnancy significantly increases the risk of congenital anomalies and adverse pregnancy outcomes compared to exposure before pregnancy, which showed similar rates to the control group. Whole-exome sequencing may help evaluate complex phenotypes in infants exposed to isotretinoin, but further research is needed.[18]

Breastfeeding considerations: Due to the risk of severe adverse reactions in nursing infants, breastfeeding is not recommended during isotretinoin treatment and for at least 8 days after the last dose. Topical medications, less likely to be absorbed by the mother, may be preferable during breastfeeding.[19]

Pediatric patients: Isotretinoin is approved for treating severe nodular acne in patients aged 12 to 17; however, its use in those younger than 12 has not been approved. According to the American Academy of Pediatrics, the recommended starting dose of isotretinoin is 0.5 mg/kg/d for the first 4 weeks to minimize initial flare-ups, followed by an increase to 1 mg/kg/d. The panel supports this approach for treating acne in adolescents and preadolescents, and agrees that isotretinoin may be considered in younger patients with severe, refractory, or scarring acne.[20]

Older patients: Acne can persist or develop in older adults, including persistent, premenstrual chin acne and sporadic acne. When it occurs, triggers such as comedogenic substances, medications, and endocrine disorders should be ruled out. Treatment in older adults emphasizes reassurance, with azelaic acid and sulfur preferred over more irritating options such as retinoids. Low-dose systemic isotretinoin may also be beneficial for some patients.[21]

Dispensing

REMS and iPLEDGE requirements (technician responsibilities):

• Verify that the patient, prescriber, and pharmacy are enrolled in iPLEDGE.
• Confirm a monthly negative pregnancy test before dispensing.
• Ensure dispensing occurs within the 7-day window after the test.
• Document dispensing electronically in the iPLEDGE system.
• Coordinate with prescribers to ensure documentation is complete and avoid treatment delays.
• Under the iPLEDGE REMS program, each brand is certified individually, and substitution may require reauthorization from the prescriber in the iPLEDGE system; therefore, technicians should not substitute one brand for another during data entry or at any other step in dispensing.

Table

Table 1. Available Oral Isotretinoin Formulations and Brand Names.

Adverse Effects

Cheilitis (dry lips) is the most common dose-dependent adverse effect, affecting approximately 90% of patients taking isotretinoin. Other common adverse effects of isotretinoin include xerosis (dry skin), xerostomia (dry mouth), rhinitis sicca (dry nose), and photosensitivity. Before starting medication, the patient should be educated on the importance of sun protection, skin moisturizers, and the use of barriers. Patients should also avoid all skin resurfacing procedures, such as waxing, dermabrasion, and laser therapy, during treatment and for at least 6 months after treatment to prevent skin irritation and scarring.

Hypertriglyceridemia and increased erythrocyte sedimentation rate are also very common adverse effects of isotretinoin therapy. Frequent monitoring for these effects is indicated during the induction and treatment periods. A rare case report of isotretinoin-induced pericardial effusion or atrial tachycardia has been reported.[22] Isotretinoin has been associated with rare cases of rhabdomyolysis, particularly when used in combination with physical exercise.[23] Although this adverse effect is uncommon, patients experiencing myalgia should be monitored for creatine phosphokinase elevation during therapy to facilitate early detection of potential rhabdomyolysis.[24]

A systematic review examined musculoskeletal adverse effects associated with isotretinoin. Common symptoms included low back pain, myalgia, arthralgia, sacroiliitis, and tendinopathy, with most symptoms appearing within a few months of treatment. Sacroiliitis was the most significant complication. The cumulative dose of isotretinoin was associated with an increased risk of low back pain; however, no significant relationship was found with HLA-B27 status. Symptoms typically resolved with the discontinuation of isotretinoin and anti-inflammatory treatments.[25]

A meta-analysis found weak evidence linking major adverse cardiovascular events to the use of isotretinoin. Case reports highlight thromboembolic events, cardiomyopathy, arrhythmias, and acute coronary syndrome, but causality remains unclear. Cardiovascular risk factors, including baseline and follow-up lipid profiles, should be assessed before and during isotretinoin therapy. If a major adverse cardiovascular event occurs, isotretinoin should be discontinued, and the relationship with the drug should be evaluated individually, considering other potential causes. Further research is needed into the underlying mechanisms.[26]

Other potential adverse effects include pruritus (itching), irritation, hair thinning, skin fragility, dry eyes, skin infections, rash, muscle aches, bone pain, and arthralgias (joint pain). Back and joint pain are most common in the pediatric population.[27] There have been controversial associations with isotretinoin in patients who are also experiencing inflammatory bowel disease or depression. However, recent meta-analyses have not shown an association between isotretinoin and these diseases. Further research is needed to better understand these potential relationships.[28]

Potential laboratory abnormalities in patients receiving isotretinoin include decreased high-density lipoprotein levels, increased liver function tests, increased creatine phosphokinase levels, decreased hemoglobin and hematocrit levels, decreased erythrocyte and leukocyte counts, and increased platelet counts. In the rare event that neutropenia or agranulocytosis should occur, isotretinoin should be discontinued.[29][30]

Drug-Drug Interactions

Vitamin A: Isotretinoin should not be co-administered with vitamin A supplements to avoid the risk of increased toxicity due to synergistic effects.

Phenytoin: Caution is recommended when administering isotretinoin with phenytoin, as concurrent use increases the risk of osteomalacia.

Tetracyclines: The concurrent administration of isotretinoin and tetracyclines is not advisable due to the risk of idiopathic intracranial hypertension (pseudotumor cerebri).[31]

Contraindications

Isotretinoin is contraindicated in patients with hypersensitivity to its components, including vitamin A and preservatives within the gel capsule.[6][32]

Box Warnings

Isotretinoin was a pregnancy category X drug under the previous FDA system and is contraindicated in pregnant women or those who may become pregnant. There have been severe, documented congenital disabilities when pregnant women have taken isotretinoin. The FDA requires prescribers and patients to register with the iPLEDGE program to prescribe and receive isotretinoin. iPLEDGE ensures that appropriate requirements are met before dispensing isotretinoin to prevent its use during pregnancy. These requirements include negative pregnancy tests and documented abstinence or the use of birth control before and while taking isotretinoin.

Warnings and Precautions

Blood donation: Patients taking isotretinoin should avoid blood donation while on isotretinoin and for 1 month after discontinuing treatment due to the risk of embryo-fetal toxicity.

Neuropsychiatric adverse effects: Cases of depression, psychosis, and suicidal ideation have been reported during isotretinoin therapy. Even though the correlation is controversial, screening for depression, suicidal ideation, past suicide attempts, and aggressive or violent behaviors should occur before prescribing isotretinoin.

Pseudotumor cerebri: Idiopathic intracranial hypertension (pseudotumor cerebri) has been presented in cases of patients taking isotretinoin with concomitant use of tetracyclines. For this reason, tetracyclines should not be administered with isotretinoin. If patients develop signs or symptoms of pseudotumor cerebri, prompt discontinuation of isotretinoin is necessary, and the patient should be referred to a neurologist for further evaluation and management.[33][34][35]

Severe cutaneous adverse reactions: Serious reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported and require prompt cessation of isotretinoin if they occur during therapy.[36]

Pancreatitis: Reports indicate acute pancreatitis in isotretinoin users with both normal and high triglyceride levels. Pancreatitis may also result from an idiosyncratic reaction. Therapy should be discontinued if pancreatitis is suspected.[37]

Hearing abnormalities: Impaired hearing, including tinnitus, has been reported in patients treated with systemic isotretinoin. In a study of 32 patients with acne vulgaris treated with 0.5 mg/kg isotretinoin for at least 4 months, audiometric tests revealed significant changes in pure-tone thresholds at 8000 Hz across various treatment periods, including pretreatment, the first week, the first month, the third month, and the sixth month. A decrease in hearing thresholds at 8000 Hz was observed by the sixth month posttreatment, but these changes improved after discontinuation of isotretinoin, suggesting that while isotretinoin can impact hearing, the effects may be reversible after treatment cessation.[38]

Ocular adverse effects: Visual disturbances, including corneal opacities, nyctalopia, and xerophthalmia, should be monitored during isotretinoin therapy.[39][40] Corneal opacities, which are more prevalent with higher dosages and in patients with keratinization disorders, typically resolve after discontinuation. Nyctalopia may persist after therapy, and patients should be cautioned about nighttime driving.[41] If visual symptoms occur, isotretinoin should be discontinued and an ophthalmologic evaluation performed.

Monitoring

Females of Child-Bearing Potential

Isotretinoin should only be prescribed to patients confirmed not to be pregnant with a negative pregnancy test from a Clinical Laboratory Improvement Amendments-certified laboratory. Two negative pregnancy tests are necessary before initiating isotretinoin therapy. The first pregnancy test should occur up to 30 days before medication initiation. The second pregnancy test must occur at least 19 days after the first negative pregnancy test and within the first 5 days of the patient's menstrual cycle. Each subsequent month, the patient must have a recorded negative pregnancy test to continue therapy. After discontinuation of treatment, a final pregnancy test should be taken 30 days following therapy completion.

Females of child-bearing potential must be on 2 effective forms of birth control or complete abstinence while receiving isotretinoin therapy. The iPLEDGE program defines abstinence as no sexual contact with any man 24 hours a day, 7 days a week. This program does not recommend abstinence as a way to prevent pregnancy while on isotretinoin. If a patient chooses birth control, one of the selected methods must be a primary form, which includes tubal sterilization, partner's vasectomy, intrauterine device, or hormonal (combination birth control pills, skin patches, shots, under-the-skin implants, or vaginal rings). Secondary forms include male latex condoms, diaphragm, cervical cap, or vaginal sponge, all with the co-administration of spermicide. Natural family planning, birth control pills without estrogen, female condoms, withdrawal, and cervical shields are not acceptable forms of birth control according to the iPLEDGE program.

Pretreatment Monitoring (All Patients)

Before initiating isotretinoin therapy, liver function tests, a fasting lipid profile (including triglycerides), blood glucose, creatine phosphokinase, and a complete blood count with differential should be obtained. Patients should also be screened for mood alteration, psychosis, aggression, suicidal ideation, skin changes, and visual changes.

Ongoing Monitoring (All Patients)

Liver function tests and lipids should be monitored every 2 weeks until a response to isotretinoin is established.[6] The consensus is to check alanine aminotransferase and triglycerides at baseline and peak doses.[42]

Acne Grading Scales

Various acne grading tools, such as global acne severity grading and multimodal digital imaging, can be used to monitor treatment response.[43]

Toxicity

Signs and Symptoms of Overdose

Reports of acute intoxication indicate exacerbations of common, well-known isotretinoin adverse effects, including cutaneous xerosis and cheilitis, vomiting, dizziness, facial flushing, headache, abdominal pain, and ataxia.[6]

Management of Overdose

There is no commonly used antidote for isotretinoin intoxication. Isotretinoin overdose symptoms typically resolve without lasting effects. Pregnant individuals or those who can become pregnant should be evaluated for pregnancy in case of overdose. Men should use a condom or avoid reproductive sexual activity for 1 month following postoverdose, as isotretinoin levels in semen may be higher. Patients who experience an overdose should not donate blood for at least a month.

Enhancing Healthcare Team Outcomes

Isotretinoin may be prescribed by any licensed clinician; however, safe and effective use requires a comprehensive understanding of its pharmacologic profile and potential adverse effects, particularly its high teratogenic risk. As a pregnancy category X medication, isotretinoin is strictly contraindicated in pregnant individuals or those who may become pregnant. Significant congenital malformations have been documented when isotretinoin is taken during pregnancy. To mitigate these risks, the FDA mandates prescriber and patient enrollment in the iPLEDGE program, which enforces stringent requirements such as negative pregnancy testing and verified use of contraception or abstinence before, during, and after therapy.[44][45]

Because isotretinoin therapy involves complex safety, regulatory, and monitoring requirements, coordinated interprofessional collaboration is essential. Pharmacists play a crucial role in ensuring iPLEDGE compliance, verifying prescriptions, and maintaining open communication between patients and prescribers. Nurses support patient education, reinforce adherence to pregnancy prevention protocols, and monitor for adverse reactions or mood changes. Clinicians must maintain clear and timely communication with nursing and pharmacy staff to resolve safety concerns and adjust therapy as necessary. In overdose situations, critical care specialists are responsible for stabilization and monitoring. This collaborative, multidisciplinary approach ensures ethical, patient-centered care by enhancing adherence, minimizing adverse events, and optimizing clinical outcomes in isotretinoin therapy.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Reynolds RV, Yeung H, Cheng CE, Cook-Bolden F, Desai SR, Druby KM, Freeman EE, Keri JE, Stein Gold LF, Tan JKL, Tollefson MM, Weiss JS, Wu PA, Zaenglein AL, Han JM, Barbieri JS. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024 May;90(5):1006.e1-1006.e30. [PubMed: 38300170]

2.

Zaenglein AL, Segal J, Darby C, Del Rosso JQ. Lidose-Isotretinoin Administered Without Food Improves Quality of Life in Patients With Severe Recalcitrant Nodular Acne: An Open-Label, Single-Arm, Phase IV Study. J Clin Aesthet Dermatol. 2020 Sep;13(9):15-20. [PMC free article: PMC7577326] [PubMed: 33133336]

3.

Everts HB, Akuailou EN. Retinoids in Cutaneous Squamous Cell Carcinoma. Nutrients. 2021 Jan 05;13(1) [PMC free article: PMC7824907] [PubMed: 33466372]

4.

Huang TC, Chang CH, Hsiao PF, Hsu CK, Lin CY, Wu CS, Yeh SP, Tsai TF. Cutaneous T-cell lymphoma: Consensus on diagnosis and management in Taiwan. J Formos Med Assoc. 2025 Oct;124(10):902-911. [PubMed: 39496538]

5.

Bayeva N, Coll E, Piskareva O. Differentiating Neuroblastoma: A Systematic Review of the Retinoic Acid, Its Derivatives, and Synergistic Interactions. J Pers Med. 2021 Mar 16;11(3) [PMC free article: PMC7999600] [PubMed: 33809565]

6.

Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, Bowe WP, Graber EM, Harper JC, Kang S, Keri JE, Leyden JJ, Reynolds RV, Silverberg NB, Stein Gold LF, Tollefson MM, Weiss JS, Dolan NC, Sagan AA, Stern M, Boyer KM, Bhushan R. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016 May;74(5):945-73.e33. [PubMed: 26897386]

7.

Assiri A, Hobani AH, AlKaabi HA, Mojiri ME, Daghriri SA, Suwaid OA, Alameer MI, Akkam MM, Alamir MA, Albarr AA, Alshaikh MR, Sumayli AM, Akkam FM, Hakami HA. Efficacy of Low-Dose Isotretinoin in the Treatment of Rosacea: A Systematic Review and Meta-Analysis. Cureus. 2024 Mar;16(3):e57085. [PMC free article: PMC11052926] [PubMed: 38681262]

8.

Angileri L, Veraldi S, Barbareschi M. Rosacea fulminans: two case reports and review of the literature. J Dermatolog Treat. 2021 Feb;32(1):110-113. [PubMed: 31169436]

9.

Koh HY, Ng SK, Tan WP. Rosacea fulminans. Indian J Dermatol Venereol Leprol. 2014 May-Jun;80(3):272-4. [PubMed: 24823417]

10.

King A, Tan MG, Kirshen C, Tolkachjov SN. Low-dose isotretinoin for the management of rosacea: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2025 Apr;39(4):785-792. [PMC free article: PMC11934015] [PubMed: 39239956]

11.

On SC, Zeichner J. Isotretinoin updates. Dermatol Ther. 2013 Sep-Oct;26(5):377-89. [PubMed: 24099068]

12.

Michael K, Tan J. Enhancing Bioavailability: Advances in Oral Isotretinoin Formulations. Skin Therapy Lett. 2024 Sep;29(5):10-12. [PubMed: 39353206]

13.

Lazorwitz A, Seale R, Davis A, Guiahi M. A pilot study on the effect of isotretinoin on serum etonogestrel concentrations in contraceptive implant users. Contraception. 2020 Jul;102(1):58-60. [PMC free article: PMC7272275] [PubMed: 32325076]

14.

Grønhøj Larsen F, Jakobsen P, Grønhøj Larsen C, Heidenheim M, Held E, Nielsen-Kudsk F. The metabolism and pharmacokinetics of isotretinoin in patients with acne and rosacea are not influenced by ethanol. Br J Dermatol. 2009 Sep;161(3):664-70. [PubMed: 19563582]

15.

Gudas LJ. Retinoid metabolism: new insights. J Mol Endocrinol. 2022 Nov 01;69(4):T37-T49. [PMC free article: PMC9561048] [PubMed: 35900851]

16.

Goldsmith LA, Bolognia JL, Callen JP, Chen SC, Feldman SR, Lim HW, Lucky AW, Reed BR, Siegfried EC, Thiboutot DM, Wheeland RG., American Academy of Dermatology. American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. J Am Acad Dermatol. 2004 Jun;50(6):900-6. [PubMed: 15153892]

17.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Nov 10, 2020. Isotretinoin. [PubMed: 31643194]

18.

Alay MT, Kalayci A, Seven M. A new perspective on isotretinoin in pregnancy: Pregnancy outcomes, evaluation of complex phenotypes, and importance of teratological counselling. Eur J Obstet Gynecol Reprod Biol. 2023 Dec;291:148-155. [PubMed: 37890418]

19.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Oct 15, 2024. Isotretinoin. [PubMed: 30000695]

20.

Eichenfield LF, Krakowski AC, Piggott C, Del Rosso J, Baldwin H, Friedlander SF, Levy M, Lucky A, Mancini AJ, Orlow SJ, Yan AC, Vaux KK, Webster G, Zaenglein AL, Thiboutot DM., American Acne and Rosacea Society. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013 May;131 Suppl 3:S163-86. [PubMed: 23637225]

21.

Marks R. Acne and its management beyond the age of 35 years. Am J Clin Dermatol. 2004;5(6):459-62. [PubMed: 15663343]

22.

Güler E, Babur Güler G, Yavuz C, Kızılırmak F. An unknown side effect of isotretinoin: pericardial effusion with atrial tachycardia. Anatol J Cardiol. 2015 Feb;15(2):168-9. [PMC free article: PMC5337018] [PubMed: 25625453]

23.

Raneses E, Schmidgal EC. Rhabdomyolysis Caused by Isotretinoin and Exercise in an Otherwise Healthy Female Patient. Cureus. 2022 Jun;14(6):e25981. [PMC free article: PMC9287672] [PubMed: 35859962]

24.

Dasgupta K, Lim P, Reedstorm H. A Common Drug With a Dangerous Side Effect: Acute Rhabdomyolysis Caused by the Synergistic Effect of Isotretinoin and Exercise in an Adolescent. Cureus. 2020 Oct 13;12(10):e10929. [PMC free article: PMC7660121] [PubMed: 33194495]

25.

Almutairi RR, Almutairi AG, Alhallafi AF, Almudawi NA, AlSulaiman MA, Shadid AM, Alharxithy R. Isotretinoin musculoskeletahl side effects: a systematic review. Dermatol Reports. 2024 Nov 21;16(4):9845. [PMC free article: PMC11694419] [PubMed: 39749120]

26.

Cowan TL, Stark M, Sarmiento S, Miller A. Systematic Review of Rare Major Adverse Cardiovascular Events Associated With the Treatment of Acne With Isotretinoin. Australas J Dermatol. 2025 May;66(3):e97-e108. [PMC free article: PMC12062722] [PubMed: 39927601]

27.

Karaosmanoğlu N, Mülkoğlu C. Analysis of musculoskeletal side effects of oral Isotretinoin treatment: a cross-sectional study. BMC Musculoskelet Disord. 2020 Sep 25;21(1):631. [PMC free article: PMC7519514] [PubMed: 32977793]

28.

Li C, Chen J, Wang W, Ai M, Zhang Q, Kuang L. Use of isotretinoin and risk of depression in patients with acne: a systematic review and meta-analysis. BMJ Open. 2019 Jan 21;9(1):e021549. [PMC free article: PMC6347928] [PubMed: 30670500]

29.

Lorenzo-Villalba N, Alonso-Ortiz MB, Maouche Y, Zulfiqar AA, Andrès E. Idiosyncratic Drug-Induced Neutropenia and Agranulocytosis in Elderly Patients. J Clin Med. 2020 Jun 10;9(6) [PMC free article: PMC7356965] [PubMed: 32531979]

30.

Ozdemir MA, Kose M, Karakukcu M, Ferahbas A, Patiroglu T, Koklu E. Isotretinoin-induced agranulocytosis. Pediatr Dermatol. 2007 Jul-Aug;24(4):425-6. [PubMed: 17845176]

31.

Reserva J, Adams W, Perlman D, Vasicek B, Joyce C, Tung R, Swan J. Coprescription of Isotretinoin and Tetracyclines for Acne is Rare: An Analysis of the National Ambulatory Medical Care Survey. J Clin Aesthet Dermatol. 2019 Oct;12(10):45-48. [PMC free article: PMC6937145] [PubMed: 32038749]

32.

Eichenfield LF, Krakowski AC. A novel patient support program to address isotretinoin adherence: proof-of-concept analysis. J Drugs Dermatol. 2015 Apr;14(4):375-9. [PubMed: 25844611]

33.

Strauss JS, Krowchuk DP, Leyden JJ, Lucky AW, Shalita AR, Siegfried EC, Thiboutot DM, Van Voorhees AS, Beutner KA, Sieck CK, Bhushan R., American Academy of Dermatology/American Academy of Dermatology Association. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007 Apr;56(4):651-63. [PubMed: 17276540]

34.

Huang YC, Cheng YC. Isotretinoin treatment for acne and risk of depression: A systematic review and meta-analysis. J Am Acad Dermatol. 2017 Jun;76(6):1068-1076.e9. [PubMed: 28291553]

35.

Lee SY, Jamal MM, Nguyen ET, Bechtold ML, Nguyen DL. Does exposure to isotretinoin increase the risk for the development of inflammatory bowel disease? A meta-analysis. Eur J Gastroenterol Hepatol. 2016 Feb;28(2):210-6. [PubMed: 26545085]

36.

Kapała J, Lewandowska J, Placek W, Owczarczyk-Saczonek A. Adverse Events in Isotretinoin Therapy: A Single-Arm Meta-Analysis. Int J Environ Res Public Health. 2022 May 26;19(11) [PMC free article: PMC9180136] [PubMed: 35682048]

37.

Dhattarwal N, Khunger N, Lal A. Isotretinoin Induced Pancreatitis: A Rare Idiosyncratic Reaction. Indian J Dermatol. 2022 Nov-Dec;67(6):781-783. [PMC free article: PMC10043673] [PubMed: 36998831]

38.

Kemeriz F, Kayabaşı S, Cevirgen Cemil B, Hızlı Ö. Evaluation of oral isotretinoin effects on hearing system in patients with acne vulgaris: Reversible or not? Dermatol Ther. 2021 Jan;34(1):e14640. [PubMed: 33278063]

39.

Lamberg O, Strome A, Jones F, Mleczek J, Jarocki A, Troost JP, Helfrich Y. Ocular side effects of systemic isotretinoin - a systematic review and summary of case reports. J Dermatolog Treat. 2023 Dec;34(1):2213364. [PubMed: 37248700]

40.

Sánchez-González MC, De-Hita-Cantalejo C, Martínez-Lara C, Sánchez-González JM. Oral isotretinoin for acne vulgaris side effects on the ocular surface: Hyaluronic acid and galacto-xyloglucan as treatment for dry eye disease signs and symptoms. Front Med (Lausanne). 2022;9:959165. [PMC free article: PMC9353322] [PubMed: 35935781]

41.

Madke B, Prasad K, Kar S. Isotretinoin-Induced Night Blindness. Indian J Dermatol. 2015 Jul-Aug;60(4):424. [PMC free article: PMC4533586] [PubMed: 26288455]

42.

Xia E, Han J, Faletsky A, Baldwin H, Beleznay K, Bettoli V, Dréno B, Goh CL, Stein Gold L, Gollnick H, Herane MI, Kang S, Kircik L, Mann J, Nast A, Oon HH, See JA, Tollefson M, Webster G, Zip C, Tan J, Tapper EB, Thiboutot D, Zaenglein A, Barbieri J, Mostaghimi A. Isotretinoin Laboratory Monitoring in Acne Treatment: A Delphi Consensus Study. JAMA Dermatol. 2022 Aug 01;158(8):942-948. [PubMed: 35704293]

43.

Bae IH, Kwak JH, Na CH, Kim MS, Shin BS, Choi H. A Comprehensive Review of the Acne Grading Scale in 2023. Ann Dermatol. 2024 Apr;36(2):65-73. [PMC free article: PMC10995619] [PubMed: 38576244]

44.

Boos MD, Ginsberg BA, Peebles JK. Prescribing isotretinoin for transgender youth: A pledge for more inclusive care. Pediatr Dermatol. 2019 Jan;36(1):169-171. [PubMed: 30318854]

45.

Lee KC, Bercovitch L. Circumventing iPLEDGE: Circumventing ethical responsibility? J Am Acad Dermatol. 2017 Dec;77(6):1185-1187. [PubMed: 29132856]

Disclosure: Hannah Pile declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.